Lana Pine

Among included RA studies, 83.3% showed significantly better clinical outcomes in patients managed with a T2T strategy compared with usual care.

After initiating treatment with ixekizumab, tender and swollen joint counts, pain, fatigue, and body surface area affected by psoriasis were significantly improved.

Nigil Haroon, MD, PhD, explains how understanding the "window of opportunity" is crucial in treating axial spondyloarthritis.

E. Michael Lewiecki, MD, discusses the significant treatment gap seen in osteoporosis and barriers to care.

An analysis of individual food groups revealed higher intakes of healthy plant foods, including tea, coffee, and whole grains were linked to a lower risk of gout.

Andrew Sharobeem, DO, discusses the major unmet needs among patients with Ehlers-Danlos Syndrome, including awareness among healthcare providers.

Swapnil Hiremath, MD, MPH, discusses resistant hypertension, including using an evidence-based approach to management and addressing non-adherence.

At the end of the study period, the median dose of daprodustat and ESA were higher among the ESA-HR cohort when compared with the non-ESA-HR group.

During follow-up, rates of incident PAD were higher among patients with depressive symptoms compared with those without depression.

A numerically slower decline in eGFR was reported in the finerenone cohort after hospitalization for heart failure when compared with placebo.

Wei Ling Lau, MD, explains the importance of medication adherence to maximize the benefits of RAASi therapy.

Wei Ling Lau, MD, explains how to enable optimal RAASi therapy while reducing hyperkalemia risk.

Michael Shlipak, MD, MPH, explains updates to the American Heart Association's cardiovascular risk equation, which now incorporates kidney function and damage through albuminuria into its components.

Jared Hassler, MD, shares his personal journey with IgAN and discusses IgAN's clinical features and diagnosis, emphasizing the importance of routine screenings for early detection.

Patients with IgAN receiving iptacopan achieved a 38.3% reduction in proteinuria at month 9.

Findings demonstrated a slower decline in kidney function for patients treated with sparsentan or irbesartan compared with standard of care in both real-world and clinical trial settings.

Kam Kalantar-Zadeh, MD, MPH, PhD, discusses his presentation focusing on dietary challenges, potassium control, and potential solutions associated with RAASi therapy.

Kam Kalantar-Zadeh, MD, MPH, PhD, addresses the challenge healthcare providers encounter in balancing the cardiovascular advantages of RAASi therapy with the potential hazards of hyperkalemia.

Maya N. Clark-Cutaia, PhD, ACNP-BC, RN, highlights strategies to improve cardiovascular disease-related outcomes in patients with ESKD.

Areef Ishani, MD, MS, discusses the results of the Diuretic Comparison Project (DCP), which compared chlorthalidone and hydrochlorothiazide for the treatment of cardiovascular diseases.

Sylvia Rosas, MD, MSCE, discusses highlights from the National Kidney Foundation's Spring Clinical Meeting, including innovations in xenotransplantation, artificial intelligence, and the interplay between kidney, heart, and metabolic diseases.

Swapnil Hiremath, MD, MPH, explains the importance of 24-hour ambulatory blood pressure monitoring (ABPM) to rule out the possibility of white coat hypertension.

In an interview with HCPLive, E. Michael Lewiecki, MD, explores the current principles of osteoporosis treatment.

Jason Busse, DC, PhD, discusses the discrepancies and contradictions across guidelines regarding the management of chronic pain.

As disparate representation in pivotal research impacts the outcomes of common diseases like lupus, clinicians and researchers alike are working to foster trust and collaboration with more patients of color.

Jason Busse, DC, PhD, highlights the modest benefits of opioids and therapeutic cannabis in managing chronic pain.

These guidelines are designed to help clinicians incorporate the latest recommendations into their clinical practice.

An IMID diagnosis or use of immunomodulatory medications were not shown to be a significant risk factor of severe COVID-19 outcomes.

These findings can be used to enhance usability of the digital health app and improve outcomes and quality of life among patients with long COVID.

Pain relief and healthcare satisfaction were significantly increased in patients who were educated about their fibromyalgia and received care from a knowledgeable clinician who gave them information and guidance.